These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31201392)

  • 1. Ripretinib turns off the switch in GIST.
    Villanueva MT
    Nat Rev Cancer; 2019 Jul; 19(7):370. PubMed ID: 31201392
    [No Abstract]   [Full Text] [Related]  

  • 2. Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study.
    Symcox M; Somaiah N
    Future Oncol; 2021 Dec; 17(36):5007-5012. PubMed ID: 34661454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ripretinib: First Approval.
    Dhillon S
    Drugs; 2020 Jul; 80(11):1133-1138. PubMed ID: 32578014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward.
    Lostes-Bardaji MJ; García-Illescas D; Valverde C; Serrano C
    Ther Adv Med Oncol; 2021; 13():1758835920986498. PubMed ID: 33473249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis.
    Gupta A; Singh J; García-Valverde A; Serrano C; Flynn DL; Smith BD
    Mol Cancer Ther; 2021 Jul; 20(7):1234-1245. PubMed ID: 33947686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs for the treatment of gastrointestinal stromal tumors.
    Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drugs in gastrointestinal stromal tumors.
    Martin-Broto J; Moura DS
    Curr Opin Oncol; 2020 Jul; 32(4):314-320. PubMed ID: 32541319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New drug approvals: Ripretinib for advanced gastrointestinal stromal tumors (GIST) in fourth or later-line therapy].
    Lemaître J; Watson S
    Bull Cancer; 2022 Mar; 109(3):250-252. PubMed ID: 35094842
    [No Abstract]   [Full Text] [Related]  

  • 9. Ripretinib (Qinlock) for GIST.
    Med Lett Drugs Ther; 2021 Apr; 63(1621):e56-e57. PubMed ID: 33830971
    [No Abstract]   [Full Text] [Related]  

  • 10. Ripretinib turns off the switch in GIST.
    Villanueva MT
    Nat Rev Drug Discov; 2019 Jul; 18(7):499. PubMed ID: 31267077
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
    Zalcberg JR; Heinrich MC; George S; Bauer S; Schöffski P; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Somaiah N; Meade J; Reichert V; Shi K; Sherman ML; Ruiz-Soto R; von Mehren M; Blay JY
    Oncologist; 2021 Nov; 26(11):e2053-e2060. PubMed ID: 34313371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates.
    Farag S; Smith MJ; Fotiadis N; Constantinidou A; Jones RL
    Curr Treat Options Oncol; 2020 May; 21(7):55. PubMed ID: 32462367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal stromal tumor: a review of current and emerging therapies.
    Al-Share B; Alloghbi A; Al Hallak MN; Uddin H; Azmi A; Mohammad RM; Kim SH; Shields AF; Philip PA
    Cancer Metastasis Rev; 2021 Jun; 40(2):625-641. PubMed ID: 33876372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical Management of Metastatic Gastrointestinal Stromal Tumors.
    Yonkus JA; Alva-Ruiz R; Grotz TE
    Curr Treat Options Oncol; 2021 Mar; 22(5):37. PubMed ID: 33743084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotyping guided ripretinib directly after the progression of first-line imatinib therapy in advanced gastrointestinal stromal tumor: a case report.
    Huang S; Guo X; Xia Y; Ding L; Zhai E; Chen S; He Y; Cai S; Zhang X
    Ann Transl Med; 2022 Jan; 10(2):118. PubMed ID: 35282043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avances en tumores del estroma gastrointestinal: ¿hacia dónde vamos?
    Fernández-Hernández JA; Cantín-Blázquez S; García-Somacarrera E; Varo-Pérez E; González-López JA; Asencio-Pascual JM; Mendiola M; Serrano C; García-Granero E; Artigas-Raventós V
    Cir Cir; 2022; 90(2):267-277. PubMed ID: 35350056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current status and progress in novel drug research for gastrointestinal stromal tumors].
    Dong Z; Li J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):911-916. PubMed ID: 32927518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
    Mohammadi M; Gelderblom H
    Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
    [No Abstract]   [Full Text] [Related]  

  • 19. Ripretinib for advanced gastrointestinal stromal tumours.
    Dekker TJA
    Lancet Oncol; 2020 Sep; 21(9):e414. PubMed ID: 32888464
    [No Abstract]   [Full Text] [Related]  

  • 20. Ripretinib for advanced gastrointestinal stromal tumours - Authors' reply.
    Blay JY; von Mehren M
    Lancet Oncol; 2020 Sep; 21(9):e415. PubMed ID: 32888465
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.